Aspen Pharmacare Holdings Stock Earnings Per Share
Aspen Pharmacare Holdings fundamentals help investors to digest information that contributes to Aspen Pharmacare's financial success or failures. It also enables traders to predict the movement of Aspen Pink Sheet. The fundamental analysis module provides a way to measure Aspen Pharmacare's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aspen Pharmacare pink sheet.
Aspen |
Aspen Pharmacare Holdings Company Earnings Per Share Analysis
Aspen Pharmacare's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Aspen Pharmacare Earnings Per Share | 0.80 X |
Most of Aspen Pharmacare's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aspen Pharmacare Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Aspen Pharmacare Holdings has an Earnings Per Share of 0.8 times. This is 90.44% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The earnings per share for all United States stocks is 74.36% higher than that of the company.
Aspen Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aspen Pharmacare's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aspen Pharmacare could also be used in its relative valuation, which is a method of valuing Aspen Pharmacare by comparing valuation metrics of similar companies.Aspen Pharmacare is currently under evaluation in earnings per share category among its peers.
Aspen Fundamentals
Return On Equity | 0.095 | |||
Return On Asset | 0.0499 | |||
Profit Margin | 0.17 % | |||
Operating Margin | 0.23 % | |||
Current Valuation | 4.58 B | |||
Shares Outstanding | 444.95 M | |||
Shares Owned By Insiders | 19.32 % | |||
Shares Owned By Institutions | 60.77 % | |||
Price To Earning | 11.83 X | |||
Price To Book | 0.98 X | |||
Price To Sales | 0.10 X | |||
Revenue | 38.61 B | |||
Gross Profit | 18.29 B | |||
EBITDA | 10.61 B | |||
Net Income | 6.49 B | |||
Cash And Equivalents | 7.88 B | |||
Cash Per Share | 17.25 X | |||
Total Debt | 105 M | |||
Debt To Equity | 0.38 % | |||
Current Ratio | 1.96 X | |||
Book Value Per Share | 159.44 X | |||
Cash Flow From Operations | 5.37 B | |||
Earnings Per Share | 0.80 X | |||
Number Of Employees | 8.58 K | |||
Beta | 0.62 | |||
Market Capitalization | 3.92 B | |||
Total Asset | 111.38 B | |||
Retained Earnings | 28.4 B | |||
Working Capital | 16.1 B | |||
Current Asset | 37.2 B | |||
Current Liabilities | 21.1 B | |||
Z Score | 22.2 | |||
Annual Yield | 0.02 % | |||
Net Asset | 111.38 B | |||
Last Dividend Paid | 3.26 |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Aspen Pink Sheet
If you are still planning to invest in Aspen Pharmacare Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aspen Pharmacare's history and understand the potential risks before investing.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Stocks Directory Find actively traded stocks across global markets | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |